skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

32 Total results for product and free and sample content found

Informatics Solutions

Deals API : Make your strongest business decisions with high-quality, detailed deals data.

Deals API : Make your strongest business decisions with high-quality, detailed deals data.

Access granular deals data you can integrate into your own data systems for a complete, informed view of markets, companies, and therapy areas.

Topic Market Intelligence Deals

In Vivo

How To Obtain Effective Relief When A Global Pandemic Disrupts Your Supply Chain

effective-relief

The COVID-19 pandemic is disrupting global supply chains and companies need effective tools to manage the related contract disputes. Sidley Austin partner Dorothee Schramm and senior associate Katie von der Weid, both specialized in international commercial disputes, provide tips to help companies manage the situation.

Topic Coronavirus Business Strategies Deals

In Vivo

In Vivo Deal Making Article Pack

In Vivo Deal Making Article Pack

Gain a view into the market gaps, opportunities, and trends in biopharma with a look at deal-making from In Vivo. Examine how deal-making has impacted the industry and shifted market dynamics and learn how you can use knowledge of these trends to inform your own strategies.

Generics Bulletin

Sun Finds US ‘Challenging’

Flags_USA_India

Sun Pharma’s Indian domestic operations posted strong sales in the third quarter, but this was not enough to prevent the company from reporting a 26% tumble in consolidated net profit in the face of a “challenging” US generics market and slow approvals for complex products.

Topic Deal trends

Generics Bulletin

Coherus Is Confident After US Ranibizumab Filing

Coherus_Is_Confident_After_US

Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

Topic Biosimilars Deal trends

Scrip

J.P. Morgan Conference Updates

JP_Morgan_Notebook_Day_1

Updates and coverage of the 2020 J.P. Morgan Healthcare Conference in San Francisco.

Scrip

Korea 2020 Outlook: Hopes Of Turnaround Amid Potential Deals, Biosimilar Launches, Biologics Law

Korea_2020_Outlook_Hopes_Of_Turnaround

After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.

Topic Clinical Trials Deal trends

Generics Bulletin

Biocon Biologics Gets True North Investment

Biocon_Biologics_Gets_True_North_Investment

Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.

Topic Deal trends Strategy

Scrip

J.P. Morgan 2020: What To Watch For At The Industry's Biggest Meeting

JP_Morgan_2020_What_To_Watch

The J.P. Morgan Healthcare conference is being held a week later than usual, which only makes us more ready to hear what the industry's leaders have in store. Here's a preview of potential hot topics.

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: